U.S. markets closed

Amicus Therapeutics, Inc. (FOLD)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
14.08-0.04 (-0.28%)
At close: 4:00PM EDT

14.08 0.00 (0.00%)
After hours: 4:01PM EDT

Sign in to post a message.
  • B
    Baseball
    trading like a deal on the way,which hopefully leaves JC behind, probably time for shareholders to buy enough to recover the $15.75 secondary
    Bullish
  • C
    ComedyClubster
    Little bit of patience is all that is required folks! Rye now, FOLD is acting like it is a MF -- before you think of profanity, . it stands for Mutual Fund. It needs to be converted into a growth stock; and that will commence anytime soon. The tutes are done having as much as they want; ~100%. Now, this will run.. hold tight... I'm thinking that in 3 years this will exceed $70!!!
  • L
    Low Voltage Joe
    How's "Dilution Therapeutics" doing...Crowley has yet to vote on his $1mm increase in salary at your expense?
  • B
    Baseball
    how does this company and we shareholders get rid of this spending character JC,he just doesn't care, right down to giving himself a 1$million dollar raise, plus sells 20,000 shs. worth of options????
    Bullish
  • A
    Arthur
    I seem to remember Sanofi’s phase 3 results fell short of Fold’s phase 2 results for Pompe disease. I apologize if I am mistaken.
  • E
    Existential Threat
    "Dilution Therapeutics "stable until the next shelf registration,
  • K
    Ksusha
    PARIS – June 16, 2020 – Sanofi’s investigational enzyme replacement therapy (ERT), avalglucosidase alfa, showed clinically meaningful improvement in critical manifestations (respiratory impairment and decreased mobility) of late-onset Pompe disease (LOPD) according to results from the Phase 3 trial presented today at a Sanofi-hosted scientific session. Avalglucosidase alfa met the primary endpoint demonstrating non-inferiority in improving respiratory function compared to alglucosidase alfa (standard of care) in patients with LOPD. These data will form the basis for global regulatory submissions anticipated in the second half of this year. The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy and Fast Track designations to avalglucosidase alfa for the treatment of patients with Pompe disease.

    https://www.sanofi.com/en/media-room/press-releases/2020/2020-06-16-14-00-00
    Read the latest news about our company
    Read the latest news about our company
    www.sanofi.com
  • P
    Padraig
    LOT of volume today. Almost 90 day avg, and 2x10 day. with 11 blocks totaling 1.644 mil shares. GOOD sign.
    Bullish
  • B
    Baseball
    remember shareholders, JC is the anchor with being a wild spender, basically the company could use another revenue source but is fine with current revenue, or just sell the company
    Neutral
  • B
    Baseball
    JC salary has just come out, of a additional $$1 million, hard to believe this guy
    Neutral
  • B
    Baseball
    how do we get JC out of this company, which has potential ,expenses are out of control, plus JC exercises continues with options at$3 and now sells at $13, directors are not doing their jobs
    Neutral
  • B
    Baseball
    the check book and JC will always have large investors worried as expenses are of zero concern,I'm not Short any more but should have been, CFO must make presentation next week
    Neutral
  • B
    Baseball
    why is JC hitting the $400 million L/C so hard, again with minimal rev. increase, is it again for salaries, while he continues to exercise $3 options and sell at $14 at the rate of 20,000 shares per month, "just greed"
    Bullish
  • B
    Baseball
    just a shame we shareholders need to endure JC, in a forum at a conference like this week, the buyers like what FOLD is about, until the expenses are exposed created by a non-business person like JC
    Bullish
  • S
    Steelingmoney
    Stochastic looks like it is coming out of an oversold position if your long term horizon is a month or two.
  • B
    Baseball
    another conference next week, we shareholders need CFO to explain cash burn rate by JC, with 2 secondary $$ money's gone and now dipping into L/C with zero increase in rev. JC needs to be quiet
    Neutral
  • B
    Baseball
    very, very nice trading day, approached 3 million shares, a couple large BUYERS that are smart as they collect shares, and won't drive price into the $17 area causing retail day traders to find stock yes i bot a couple thousand additional
    Bullish
  • d
    dcaf7
    From 2ndQ financial results.
    "Cash position sufficient to achieve self-sustainability without the need for any future dilutive financings."
    Good to know
  • B
    Baseball
    DO we have any clue JC got the picture ,he's not to be exercising options at $3 and selling shares at $15
    Bullish
  • B
    Baseball
    conference in 2 days for FOLD,THIS HAS to be a much better presentation and given by CFO $3 options exercising by JC does not go over well ,analyst rec. are coming in around $25 which is good, JC must be kept under wraps
    Neutral